跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PCSK9 ligands
首页
药物
PCSK9 ligands
PCSK9 ligands
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
US 10034892 B2
申请人: SRX CARDIO LLC
优先权: 2015
US
5 件公开
RNAI AGENTS FOR INHIBITING EXPRESSION OF PCSK9, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
EP 4673545 A2
申请人: ARROWHEAD PHARMACEUTICALS INC
优先权: 2023
CN
EP
US
WO
4 件公开
Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US 10568882 B2
申请人: SRX CARDIO LLC
优先权: 2016
US
3 件公开
Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
US 10821106 B2
申请人: SRX CARDIO LLC
优先权: 2016
US
2 件公开
Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US 10865185 B2
申请人: SRX CARDIO LLC
优先权: 2016
US
2 件公开
Molecular structure capable of inhibiting PCSK9 expression and pharmaceutical composition
CN 116710468 A
申请人: SIRNAOMICS INC
优先权: 2021
CN
2 件公开
SiRNA for simultaneously inhibiting expression of two target genes, medicine and application of siRNA and medicine
CN 121006363 A
申请人: GUANGZHOU BEBETTER MEDICINE CO LTD
优先权: 2023
CN
2 件公开
Proprotein convertase subtilisin/kexin type 9 allosteric binding ligands to modulate serum low density lipoprotein
CN 105378159 A
申请人: SRX CARDIO LLC
优先权: 2014
CN
Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
US 10287317 B2
申请人: SRX CARDIO LLC
优先权: 2015
US
RNAI AGENT TARGETING ANGPTL3 AND PCSK9 AND USE THEREOF
WO 2026179917 A1
申请人: YUN HO BIO CO LTD
优先权: 2025
WO
药物
反馈